Advertisement

Adjuvant Systemic Therapy: The Issues of Timing and Sequence

  • M. Castiglione-Gertsch
  • R. D. Gelber
  • A. Goldhirsch
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 140)

Abstract

Adjuvant systemic therapy in breast cancer has been widely used during the last three decades and has been shown to reduce relapses and mortality (Early Breast Cancer Trialist’s Collaborative Group 1992). The rationale for its introduction was that adjuvant treatment may kill tumor cells released into the circulation at the time of primary surgery. Subsequent hypotheses ascribe the high risk for systemic relapse to micrometastases already present at the time of breast cancer diagnosis. Although the interval from breast cancer diagnosis to postoperative adjuvant therapy is short compared to the presumed preclinical duration of tumor growth, it appears that early chemotherapy onset may be advantageous in terms of tumor cell kill and that a delay in starting adjuvant treatments may result in increased resistance to cytotoxics (Goldie and Coldman 1979).

Keywords

Breast Cancer Adjuvant Systemic Therapy Primary Chemotherapy Early Breast Cancer Trialist International Breast Cancer Study Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bonadonna G, Veronesi U, Brambilla C (1990) Primary chemotherapy to avoid mastectomy in tumours with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539–45PubMedCrossRefGoogle Scholar
  2. Bonadonna G, Valagussa P, Brambilla C, Ferrari L (1993) Preoperative chemotherapy in operable breast cancer. Lancet 3341: 1485CrossRefGoogle Scholar
  3. Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: pp 1–5 and pp 71–85Google Scholar
  4. Fisher B, Mamounas E (1995) Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13: 537–540PubMedGoogle Scholar
  5. Fisher B, Wickerham DL (1991) Preoperative systemic therapy for the treatment of primary breast cancer. In: Powles TJ, Smith IE (eds) Medical management of breast cancer. Dunitz, London, pp 281–286Google Scholar
  6. Fisher B; Slack N, Katrych D, Wolmark N (1975) Ten year follow-up results of patients with carcinoma of the breast in a co—operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528–534PubMedGoogle Scholar
  7. Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488–1492PubMedGoogle Scholar
  8. Fisher B, Redmond C, Brown A (1986) Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5—year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 4: 459–471PubMedGoogle Scholar
  9. Forrest APM, Levack PA, Chetty U (1986) A human tumour model. Lancet i:840–842Google Scholar
  10. Goldenberg GJ, Froese EK (1985) Antagonism of the cytocydal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 34: 763–770PubMedCrossRefGoogle Scholar
  11. Goldie JH, Coldman AJ (1979) A mathematical model of relating the drug—sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733PubMedGoogle Scholar
  12. Goldhirsch A, Gelber RD, Castiglione M, Price KN, Rudenstam C-M, Lindtner J, Collins J, Senn H-J, Brunner KW, Galligioni E, Cavalli F, Gudgeon A, CortesFunes H, Tattersall M, Marini G, Byrne M, Snyder R, Forbes J, Hürny C, Coates A (1994) For the international Breast Cancer Study Group. Present and future projects of the International Breast Cancer Study Group. Cancer 74: 1139–1149Google Scholar
  13. Goldhirsch A, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS, Rudenstam CM, Collins J, Lindtner J, Hacking A, Marini G, Byrne M, Cortés-Funes H, Schnürch G, Brunner KW, Tattersall MHN, Forbes J, Senn HJ (1994) Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343: 377–381PubMedCrossRefGoogle Scholar
  14. Jacquillat C, Weil M, Baillet F (1990) Results of neoadjuvant chemotherapy and radiation therapy in the breast—conserving treatment of 250 cancer patients with all stages of infiltrative breast cancer. Cancer 66: 119–129PubMedCrossRefGoogle Scholar
  15. Jones AL, Smith IE, O’Brien MER, Talbot D, Walsh G, Ramage F, Robertshaw H, Ashley S (1994) Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 12 (6): 1259–1265PubMedGoogle Scholar
  16. Ludwig Breast Cancer Study Group (1988) Combination adjuvant chemotherapy for node-positive breast cancer. Inadequacy of a single perioperative cycle. N Engl J Med 319: 677–683CrossRefGoogle Scholar
  17. Ludwig Breast Cancer Study Group (1989) Prolonged disease—free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320: 491–496CrossRefGoogle Scholar
  18. Mauriac L, Durant M, Avril A, Dilhuydy JM (1991) Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3 cm: results of a randomized trial in a single center. Ann Oncol 2: 347–354PubMedGoogle Scholar
  19. Nissen-Meyer R, Kjellgren K, Malmio K, Mansson B, Norin T (1978) Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy from breast cancer. Cancer 41: 2088–2098PubMedCrossRefGoogle Scholar
  20. Osborne CK, Kitten L, Arteaga CL (1989) Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7: 710–717PubMedGoogle Scholar
  21. Smith IE, Jones AL, O’Brien MER, McKinna JA, Sacks N, Baum M (1993) Primary medical (neo—adjuvant) chemotherapy for operable breast canncer. Eur J Cancer 29: 592–595CrossRefGoogle Scholar
  22. Speer JF, Petrosky VE, Retsky MW, Wardwell RH (1984) A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 44: 4124–4130PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • M. Castiglione-Gertsch
    • 1
  • R. D. Gelber
    • 2
  • A. Goldhirsch
    • 3
  1. 1.International Breast Cancer Study GroupCoordinating CenterBernSwitzerland
  2. 2.International Breast Cancer Study Group Statistical CenterDana Farber Cancer InstituteBostonUSA
  3. 3.Servizio Oncologico CantonaleOspedale CivicoLuganoSwitzerland

Personalised recommendations